Market
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight
Alcon and RxSight announced a co-development partnership valued at up to $200 million to create a tunable presbyopia-correcting intraocular lens (PCIOL) for cataract patients. The collaboration combines Alcon's surgical expertise with RxSight's light-adjustable lens technology to deliver customizable vision correction after implantation.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network